Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

The pivotal multicentre, double-blind, randomised, placebo-controlled Phase 3 PANAMO trial of vilobelimab in mechanically ventilated COVID-19 patients.

Publication · 2024-10-26

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

Request a copy

Related services

Resource library

All white papers, case studies, publications and blogs.

Explore →

Publications

Peer-reviewed and journal articles.

Explore →

Contact us

Talk to a senior contact about the work behind this.

Explore →